Emsley R, et al. – This investigation determined the impacts of 1–month paliperidone palmitate (PP1M) for the treatment of schizophrenia and related psychotic disorders in terms of outcomes reported in real–world evidence studies. According to the real–world data, PP1M is better than oral antipsychotics in delaying the time to relapse or treatment failure. The pharmacoeconomic data indicate that the advantages of PP1M compared with oral antipsychotics are not correlated with an increased total cost for healthcare providers.